BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26423697)

  • 1. Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target.
    Chen M; Peters A; Huang T; Nan X
    Mini Rev Med Chem; 2016; 16(5):391-403. PubMed ID: 26423697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway.
    Nan X; Tamgüney TM; Collisson EA; Lin LJ; Pitt C; Galeas J; Lewis S; Gray JW; McCormick F; Chu S
    Proc Natl Acad Sci U S A; 2015 Jun; 112(26):7996-8001. PubMed ID: 26080442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biology, pathology, and therapeutic targeting of RAS.
    Rhett JM; Khan I; O'Bryan JP
    Adv Cancer Res; 2020; 148():69-146. PubMed ID: 32723567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the RAS-dependent chemoresistance: The Warburg connection.
    Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
    Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ras and exosome signaling.
    Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
    Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The renewed battle against RAS-mutant cancers.
    Zhang F; Cheong JK
    Cell Mol Life Sci; 2016 May; 73(9):1845-58. PubMed ID: 26892781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers.
    Jang H; Muratcioglu S; Gursoy A; Keskin O; Nussinov R
    Biochem J; 2016 Jun; 473(12):1719-32. PubMed ID: 27057007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct inhibition of RAS: Quest for the Holy Grail?
    Spencer-Smith R; O'Bryan JP
    Semin Cancer Biol; 2019 Feb; 54():138-148. PubMed ID: 29248537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
    Sacco E; Spinelli M; Vanoni M
    Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
    Delire B; Stärkel P
    Eur J Clin Invest; 2015 Jun; 45(6):609-23. PubMed ID: 25832714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of K-Ras plasma membrane localization.
    Cho KJ; van der Hoeven D; Hancock JF
    Enzymes; 2013; 33 Pt A():249-65. PubMed ID: 25033808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking Ras inhibition as an antitumor strategy.
    Marín-Ramos NI; Ortega-Gutiérrez S; López-Rodríguez ML
    Semin Cancer Biol; 2019 Feb; 54():91-100. PubMed ID: 29409706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies to target RAS-mutant cancers.
    Ryan MB; Corcoran RB
    Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K-Ras protein as a drug target.
    McCormick F
    J Mol Med (Berl); 2016 Mar; 94(3):253-8. PubMed ID: 26960760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New druggable targets in the Ras pathway?
    Matallanas D; Crespo P
    Curr Opin Mol Ther; 2010 Dec; 12(6):674-83. PubMed ID: 21154159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.
    Lu S; Jang H; Gu S; Zhang J; Nussinov R
    Chem Soc Rev; 2016 Sep; 45(18):4929-52. PubMed ID: 27396271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Past, Present, and Future of Targeting Ras for Cancer Therapies.
    Tan Z; Zhang S
    Mini Rev Med Chem; 2016; 16(5):345-57. PubMed ID: 26423695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
    Aguilar BJ; Zhou H; Lu Q
    Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis.
    Eckert LB; Repasky GA; Ulkü AS; McFall A; Zhou H; Sartor CI; Der CJ
    Cancer Res; 2004 Jul; 64(13):4585-92. PubMed ID: 15231670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.